Mayne Pharma Group (ASX:MYX) - Aktienkurs, Nachrichten und Analyse

MYX Aktienübersicht

MYX grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	3/6
Künftiges Wachstum	4/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	5/6
Dividenden	0/6

Belohnungen

Prognostiziertes Gewinnwachstum 110.04% pro Jahr

Im Vergleich zu Wettbewerbern und der Branche gut bewertet

Risikoanalyse

Hat weniger als 1 Jahr Cash Runway

Mayne Pharma Group Limited Wettbewerber

Vita Life Sciences

ASX:VLS

AU$118.4m

Incannex Healthcare

ASX:IHL

AU$65.1m

Medical Developments International

ASX:MVP

AU$50.7m

Syntara

ASX:SNT

AU$59.0m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Mayne Pharma Group
Historische Aktienkurse
Aktueller Aktienkurs	AU$4.43
52-Wochen-Hoch	AU$7.46
52-Wochen-Tief	AU$3.74
Beta	1.24
11 Monat Veränderung	-1.56%
3 Monate Veränderung	14.18%
1 Jahr Veränderung	10.75%
33 Jahre Veränderung	-27.38%
5 Jahre Veränderung	-61.14%
Veränderung seit IPO	-63.08%

Aktuelle Nachrichten und Updates

A Piece Of The Puzzle Missing From Mayne Pharma Group Limited's (ASX:MYX) 30% Share Price Climb

Sep 01

Recent updates

A Piece Of The Puzzle Missing From Mayne Pharma Group Limited's (ASX:MYX) 30% Share Price Climb

Sep 01

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Mar 06

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Mar 01

We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope

Nov 16

Mayne Pharma Group (ASX:MYX) Is Making Moderate Use Of Debt

Nov 10

Mayne Pharma Group (ASX:MYX) Is Carrying A Fair Bit Of Debt

May 17

Is Mayne Pharma Group Limited (ASX:MYX) Trading At A 37% Discount?

Mar 22

How Many Mayne Pharma Group Limited (ASX:MYX) Shares Did Insiders Buy, In The Last Year?

Mar 01

What You Need To Know About Mayne Pharma Group Limited's (ASX:MYX) Investor Composition

Feb 08

Mayne Pharma Group Limited's (ASX:MYX) Shift From Loss To Profit

Jan 18

Mayne Pharma Group's (ASX:MYX) Shareholders Are Down 75% On Their Shares

Dec 27

Would Mayne Pharma Group (ASX:MYX) Be Better Off With Less Debt?

Dec 09

A Quick Analysis On Mayne Pharma Group's (ASX:MYX) CEO Compensation

Nov 24

Aktionärsrenditen

	MYX	AU Pharmaceuticals	AU Markt
7D	3.0%	3.4%	0.2%
1Y	10.8%	64.3%	16.6%

Rendite im Vergleich zur Industrie: MYX unter dem Niveau der Branche Australian Pharmaceuticals , die im vergangenen Jahr eine Rendite von 64.3% erzielte.

Rendite vs. Markt: MYX hinter dem Markt Australian zurück, der im vergangenen Jahr eine Rendite von 16.6 erzielte.

Preisvolatilität

Is MYX's price volatile compared to industry and market?
MYX volatility
MYX Average Weekly Movement	7.0%
Pharmaceuticals Industry Average Movement	12.0%
Market Average Movement	8.4%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.5%

Stabiler Aktienkurs: MYX hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: MYXDie wöchentliche Volatilität (7%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2005	n/a	Shawn O’Brien	www.maynepharma.com

Die Mayne Pharma Group Limited, ein Spezialpharmaunternehmen, produziert und vertreibt pharmazeutische Markenprodukte und Generika in Australien, Neuseeland, den Vereinigten Staaten, Kanada, Europa, Asien und international. Das Unternehmen ist in drei Segmenten tätig: Frauengesundheit, Dermatologie und International. Es bietet orale Arzneimittelverabreichungssysteme, Auftragsentwicklung und -herstellung für Drittkunden an und vertreibt pharmazeutische Spezialprodukte in den Therapiebereichen Dermatologie, Frauengesundheit und Infektionskrankheiten.

Mayne Pharma Group Limited's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Mayne Pharma Group im Vergleich zum Marktanteil des Unternehmens?
MYX grundlegende Statistiken
Marktanteil	AU$359.49m
Gewinn(TTM)	-AU$168.62m
Umsatz(TTM)	AU$388.40m

0.9x

Kurs-Umsatz-Verhältnis

-2.1x

Kurs-Gewinn-Verhältnis

Ist MYX zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
MYX Gewinn- und Verlustrechnung (TTM)
Einnahmen	AU$388.40m
Kosten der Einnahmen	AU$169.62m
Bruttogewinn	AU$218.78m
Sonstige Ausgaben	AU$387.39m
Umsatz	-AU$168.62m

Zuletzt gemeldete Gewinne

Jun 30, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-2.08
Bruttomarge	56.33%
Nettogewinnspanne	-43.41%
Schulden/Eigenkapital-Verhältnis	7.0%

Wie hat sich MYX auf lange Sicht entwickelt?

Historische Performance und Vergleiche

MYX Aktienübersicht

Belohnungen

Risikoanalyse

Mayne Pharma Group Limited Wettbewerber

ASX:VLS

AU$118.4m

ASX:IHL

AU$65.1m

ASX:MVP

AU$50.7m

ASX:SNT

AU$59.0m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

A Piece Of The Puzzle Missing From Mayne Pharma Group Limited's (ASX:MYX) 30% Share Price Climb

Price target decreased by 12% to AU$6.09

New major risk - Financial position

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

New minor risk - Profitability

Recent updates

A Piece Of The Puzzle Missing From Mayne Pharma Group Limited's (ASX:MYX) 30% Share Price Climb

Price target decreased by 12% to AU$6.09

New major risk - Financial position

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

New minor risk - Profitability

Consensus revenue estimates increase by 14%, EPS downgraded

First half 2024 earnings released: AU$0.88 loss per share (vs AU$1.38 loss in 1H 2023)

Forecast to breakeven in 2026

Mayne Pharma Group Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Mayne Pharma Group Limited to Report First Half, 2024 Results on Feb 26, 2024

High number of new directors

Consensus estimates of losses per share improve by 13%

Mayne Pharma Group Limited Approves Election of Anne Lockwood

Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023

Independent Non-Executive Director recently bought AU$69k worth of stock

Consensus estimates of losses per share improve by 13%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Financial data availability

Mayne Pharma Group Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023

Independent Non-Executive Chairman recently bought AU$74k worth of stock

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Consensus revenue estimates fall by 19%

Price target decreased by 24% to AU$3.86

First half 2023 earnings released: AU$0.078 loss per share (vs AU$0.62 loss in 1H 2022)

Mayne Pharma Group Limited to Report First Half, 2023 Results on Feb 28, 2023

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces US Launch of Haloette, a Generic Version of Nuvaring

Inaugural dividend of AU$0.065 per share

Consensus revenue estimates fall by 11%

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

Analysts Just Slashed Their Mayne Pharma Group Limited (ASX:MYX) EPS Numbers

Consensus forecasts updated

Price target decreased to AU$0.37

Is Mayne Pharma Group (ASX:MYX) Using Too Much Debt?

High number of new directors

High number of new directors

Mayne Pharma Group Limited Declares Fully Franked Special Dividend, Payable on 27 January 2023

Catalent, Inc. (NYSE:CTLT) acquired Metrics, Inc. from Mayne Pharma Group Limited (ASX:MYX) for approximately $480 million.

Mayne Pharma Group Limited Announces Executive Changes Effective from 1 October 2022

Price target decreased to AU$0.40

Mayne Pharma Group Limited Announces Management Changes

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Scott Richards Plans to Retire as CEO of Mayne Pharma Group Limited

Price target increased to AU$0.43

FDA Grants Approval to Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA of the Abbreviated New Drug Application (Anda) for Haloette

Mayne Pharma Group Limited and Mithra Pharmaceuticals, Sa Announces NEXTSTELLIS Oral Contraceptive Now Available in Australia

Mayne Pharma Group Limited Announces CFO Changes

Price target decreased to AU$0.36

Is Mayne Pharma Group (ASX:MYX) A Risky Investment?

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Forecast breakeven date pushed back to 2024

First half 2022 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 97%

Mayne Pharma Expands U.S Dermatology Portfolio

Price target increased to AU$0.48

Insufficient new directors

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Therapeutic Goods Administration Approval of NEXTSTELLIS® Oral Contraceptive

We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope

Erträge & Einnahmen